Spencer Ricks, Kristen Grannis, Peter Prial, Andrew Rondeau
January 24, 2026
Latham Advises Invetx in its US$60.5 Million Series B Financing
1 min
AI-made summary
- Invetx, a company specializing in protein-based therapeutics for animal health, has raised US$60.5 million in an oversubscribed Series B financing round
- The funding was led by F-Prime Capital, Novo Holdings, GV, and Eight Roads, with participation from existing investors
- The capital will be used to advance Invetx's monoclonal antibody pipeline and seek market approvals for treatments targeting chronic and serious diseases in dogs and cats
- Latham & Watkins advised Invetx on the financing.
Invetx, a pioneer in protein-based therapeutics for animal health, has announced that it has raised US$60.5 million in an oversubscribed Series B financing. The investment was led by F-Prime Capital, Novo Holdings, GV (formerly Google Ventures) and Eight Roads, with participation from existing investors Anterra Capital, Casdin Capital and funds managed by Tekla Capital Management, LLC. The proceeds allow the company to advance its monoclonal antibody (mAb) pipeline and pursue market approvals for therapeutics targeting chronic and serious diseases in dogs and cats. Latham & Watkins advised Invetx on its financing round with a corporate deal team led by Boston partners Spencer Ricks and Kristen Grannis, with associates Peter Prial and Andrew Rondeau.~~
Article Author
Spencer Ricks, Kristen Grannis, Peter Prial, Andrew Rondeau
The Sponsor